by Eclosion Team | Jul 13, 2021 | Uncategorized
Geneva, Switzerland, July 13, 2021 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as...
by Eclosion Team | Jul 5, 2021 | Uncategorized
Enters collaboration with the FondaMental Foundation to speed development of diagnostic and therapeutic options for patients▪ Data provides a biologic rationale to the long-term neuropsychiatric symptoms affecting an important subset of post-COVID-19...
by Eclosion Team | Apr 15, 2021 | Uncategorized
Data published in the Lancet’s EBioMedicine shows that the pathogenic envelope protein of the human endogenous retrovirus W (HERV-W ENV) is found on lymphocytes of hospitalized patients with COVID-19, and that its level of expression is associated with disease...
by Eclosion Team | Mar 2, 2021 | Uncategorized
DSMB confirms higher doses of temelimab in ProTEct-MS Phase 2 study are well tolerated▪ Study conducted at Karolinska Institutet’s Academic Specialist Center (ASC) in Stockholm▪ Phase 2 top-line results on track to be reported in Q1 2022Geneva,...
by Eclosion Team | Nov 3, 2020 | Uncategorized
Genkyotex (Euronext Paris & Brussels: FR0013399474 –GKTX), a biopharmaceutical company and the leader in NOX therapies, announced the closing of the acquisition by Calliditas Therapeutics AB (“Calliditas”; Nasdaq OMX –CALTX; NASDAQ -CALT) of 62.7% of Genkyotex in...